SCHEMBL91600

SCHEMBL91600

Cc1ccc(NC(=O)c2nn(C)c3ccccc23)c(Br)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.55
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
NFKB1 P19838 2/20 0.55
NFKB2 Q00653 2/20 0.55
RELA Q04206 2/20 0.55
LMNA P02545 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MAPT P10636 3/20 0.54
GAA P10253 1/20 0.54
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
KMT2A Q03164 1/20 0.50
BRD4 O60885 2/20 0.49
AHR P35869 1/20 0.47
LCK P06239 1/20 0.47
CSK P41240 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL91590 0.88 ALDH1A1 (0.55) SMN1; SMN2NPC1RAB9ALMNAMAPT
SCHEMBL10273937 0.86 THRB (0.56) NPC1RAB9ALMNAMAPTGAA
SCHEMBL91601 0.84 KDM4E (0.54) LMNAMAPTGAAKDM4EALDH1A1
SCHEMBL14772008 0.83 KDM4E (0.50) SMN1; SMN2LMNAMAPTKDM4EALDH1A1
SCHEMBL91595 0.80 KDM4E (0.58) KDM4EALDH1A1LCKCSKELANE
SCHEMBL10273857 0.78 NPC1 (0.54) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL92201 0.77 HIF1A (0.58) SMN1; SMN2NPC1RAB9ANFKB1NFKB2
SCHEMBL92358 0.76 KDM4E (0.53) LMNAKDM4EALDH1A1LCKCSK
SCHEMBL92552 0.76 KDM4E (0.53) LMNAGAAKDM4EALDH1A1MEN1
SCHEMBL91588 0.76 KDM4E (0.53) LMNAGAAKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 SMN1; SMN2 4739/4885NPC1 680/4885RAB9A 1503/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 SMN1; SMN2 4702/4885NPC1 551/4885RAB9A 1491/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 SMN1; SMN2 4787/4885NPC1 624/4885RAB9A 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.